Corvus Pharmaceuticals, Inc. (CRVS) Financial Statements
Free cash flow over the same period: -$45.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRVSCorvus Pharmaceuticals, Inc.Follow CRVS — free
—
Price chart with a free account
- Market cap
- 885.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 29.4 | 46.3 | 38.6 | 38.0 | 31.8 | 29.1 | 24.5 | 16.5 | 19.4 | 33.7 | 45.5 | |
| Operating income | -37.0 | -56.5 | -49.2 | -48.9 | -43.8 | -38.6 | -32.6 | -23.4 | -27.5 | -43.0 | -57.0 | |
| Pre-tax income | -36.4 | -55.7 | -46.9 | -46.7 | -6.0 | -43.2 | -41.3 | -21.7 | -59.1 | -13.3 | -51.8 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net income | -36.4 | -55.7 | -46.9 | -46.7 | -6.0 | -43.2 | -41.3 | -27.0 | -62.3 | -15.3 | -54.1 | |
| Diluted EPS ($) | -2.36 | -2.72 | -1.71 | -1.59 | -0.20 | — | -0.89 | -0.56 | -1.02 | -0.53 | -0.58 | |
| Diluted shares (mn) | — | — | — | — | — | — | 46.6 | 48.0 | 61.0 | 79.7 | — |
USD millions · SEC XBRL
Corvus Pharmaceuticals, Inc. — questions
- What is Corvus Pharmaceuticals, Inc.'s net income?
- -$54.1M over the twelve months to 2026-06-30.
- What is Corvus Pharmaceuticals, Inc.'s free cash flow?
- -$45.2M over the twelve months to 2026-06-30.
- What are Corvus Pharmaceuticals, Inc.'s diluted earnings per share?
- $-0.58 over the twelve months to 2026-06-30.
Every figure on this page comes from Corvus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.